Publication date: Jun 28, 2025
The company is known for its Targeted Hyperthermia therapy, a photothermal cancer treatment that uses therapeutic heat to treat solid tumors. This approval allows the company to begin enrolling patients for the clinical trial, which will assess the safety, tolerability, and preliminary efficacy of the THT treatment. This therapy aims to be safe, effective, minimally invasive, and cost-competitive, serving as a valuable adjunct to drug therapy and other cancer treatments.
| Concepts | Keywords |
|---|---|
| Investing | Approval |
| Nanotech | Clinical |
| Summer | Company |
| Tolerability | Market |
| Tumors | Melanoma |
| Nanotech | |
| Smart | |
| Sona | |
| Stock | |
| Stocks | |
| Therapy | |
| Tipranks | |
| Treatment | |
| Trial | |
| Tse |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Gold |
| disease | MESH | cancer |
| pathway | KEGG | Melanoma |
| disease | MESH | Hyperthermia |
| disease | MESH | Melanoma |
Original Article
(Visited 4 times, 1 visits today)